Roche launches a special program for the combination of digestive tract tumor immunotherapy.

On July 6, Roche Pharmaceuticals China announced that it will officially launch a special program dedicated to China's "Joint TherapeuticSis Cooperation in Digestive Tract Tumors" for China, which will support innovative Chinese companies in the development of new therapies for digestive tract tumors, and provide a variety of support including funding, free research drugs and research and development strategies.According to the 2019 China Cancer Report released by the National Cancer Center of
, the incidence of gastrointestinal tumors such as stomach cancer, liver cancer and esophageal cancer is in the top 10, and the overall five-year survival rate of most patients with digestive tract tumors is lower.
the "Roche Digestive Tract Tumor Immunotherapy Joint Treatment Co-operation Program" will be open to all Chinese innovative pharmaceutical companies within 5 years, specific support methods include, but not limited to, to Chinese pharmaceutical companies to provide Roche cancer immune products Tai Sanqi (Atilijusmin) and the target drug Avetin (Bevaljusma) research drugs, through joint research with domestic innovative pharmaceutical companies in the research of drugs, to explore innovative digestive tract cancer treatment. The program will also provide research and development funding on the basis of mutual agreement, and roche pharmaceuticals will also provide scientific and research support to innovative pharmaceutical companies in China in the course of the partnership to help them optimize their strategies and accelerate the research and development process.
the "Roche Digestive Tract Tumor Immune Joint Treatment Co-operation Program"
partner
open application for all Chinese innovative pharmaceutical enterprises
cooperation scope / requirements:
1. Innovative molecules, innovative targets or innovative technologies
. Mechanism of action clear
3. Property rights/ patent clarity
4. The scientific basis of the drug joint reasonable
5. The product has not yet been listed
cooperation mode:
1. China's innovative pharmaceutical enterprises put forward the need for cooperation and provide the necessary pre-
2. After the Roche Pharmaceutical team evaluates the feasibility of the two sides signed a cooperation agreement
3. Research and development is the best way to
the application
china.collaboration@roche.com
.